Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification

Gilead's Trodelvy just landed a front-line triple-negative breast cancer approval — and is staring down Keytruda in one of oncology's most contested settings.

Lilly deepens a nearly two-billion-dollar China partnership on the same day HHS moves to reshore early drug research. Plus, Novartis puts a hundred and five million behind undruggable targets, and the ADC class is having its most revealing week of the year.

Welcome to The Pharma Closeout for Wednesday, June 24th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

The FDA approved Gilead's Trodelvy — sacituzumab govitecan — for first-line triple-negative breast cancer. Trodelvy already had later-line metastatic TNBC, but front-line positioning rewrites the commercial equation entirely. TNBC is roughly ten to fifteen percent of all breast cancers, and Gilead now goes head-to-head with Keytruda plus chemotherapy where treatment decisions actually start. This is the oncology growth story beyond HIV and HCV that Gilead has been building toward. And for anyone who's followed this company's portfolio evolution, front-line TNBC is about as high-profile a commercial proof point as you can engineer in solid tumors.

The population is larger, but the clinical bar is different. Front-line patients have more therapeutic runway and lower tolerance for toxicity tradeoffs. Whether community oncologists reach for Trodelvy or stay with Keytruda-based regimens will come down to label specifics and how convincingly Gilead frames the risk-benefit profile at launch. There's a very real behavioral question here — Keytruda-based combos are deeply embedded in first-line protocols, and switching costs in oncology are not just clinical, they're institutional. Gilead's medical affairs team needs to move fast on KOL engagement and guideline discussions, because inertia in community practice is fierce.

Gilead closed with modest gains, showing steady performance in today's trading — market cap north of a hundred and fifty-five billion — while the biotech sector ran up one point four two percent on the day. A front-line breast cancer approval that can't outrun the sector tells you the Street had this priced in. The one-year analyst target sits at a hundred and fifty-seven fifty-seven, so there's room — but the market wants prescription data, not press releases. The implication is straightforward: this stock doesn't rerate on the approval itself. It rerates on the launch curve.

The priced-in thesis holds only if launch execution delivers. And the ADC backdrop this week doesn't exactly inspire class-wide confidence. Yesterday, Pfizer's sigvotatug vedotin failed in late-stage lung cancer. Today, ADC Therapeutics announced seventeen percent staff cuts tied to Zynlonta safety concerns. Trodelvy wins, but the class is not winning uniformly. And I want to be precise about why that matters commercially — payer conversations around ADCs are increasingly class-level. If the narrative hardens that ADCs carry outsized safety risk, even an approved product with clean data faces formulary headwinds it shouldn't have to fight.

Three ADC stories in two days — one major approval, one pivotal failure, one safety-driven restructuring. If you hold ADC exposure, this week just did your differentiation work for you.

The pharmacology demands that differentiation. Zynlonta's PBD dimer and Trodelvy's SN-38 topoisomerase inhibitor carry fundamentally different safety profiles — lumping them together after a headline misreads the chemistry. And paradoxically, if ADC Therapeutics retreats and Pfizer's lung program stalls, Trodelvy's competitive position within the class sharpens. That's the real read-through for Gilead. Fewer credible competitors in the ADC space means Trodelvy's safety and efficacy profile gets compared against a shrinking peer set — and that comparison only gets more favorable the more others falter.

Which means Gilead's competitive moat in the ADC space may actually be widening at exactly the moment the front-line label unlocks the larger revenue opportunity. That's a rare convergence — and if the launch data cooperates in the first two quarters, the Street will have to revisit the priced-in assumption.

That ADC divergence story will play out over quarters. But shifting to the deal side — Lilly keeps writing checks. Eli Lilly expanded its partnership with Chinese biotech Abbisko Therapeutics in a new discovery collaboration worth up to one point nine billion dollars, building on an existing pact from 2022. Lilly closed up point nine two percent — the Street reads this as accretive, not dilutive. Let's bring in Marcus Webb on the deal structure.

Novartis went a different direction — paying a hundred and five million dollars upfront to Antares Therapeutics for a small molecule discovery collaboration targeting multiple undruggable cancer targets. Adam Friedman's Antares team is going after targets that have resisted drug development for decades. That kind of upfront at the discovery stage tells you Novartis is betting on the platform, not a single molecule.

Which makes it a chemistry wager, not a biology wager. If Antares has genuine chemical matter against transcription factors or high-value protein-protein interactions, the price is defensible. The proof comes when Novartis nominates its first targets and we see what the hit rates look like. And let's be clear about the strategic logic — if even one of those undruggable targets yields a clinical candidate, the return on a hundred and five million is asymmetric. Novartis is effectively buying a portfolio of lottery tickets where the underlying science, if it translates, could open entirely new therapeutic categories.

Also worth noting — Ollin raised three hundred and thirty million dollars for pivotal trials of a Vabysmo challenger in ophthalmology. RQ Bio secured a hundred and fifteen million for virus-targeting antibodies, including a preventive flu drug. And Lilly's 340B contract pharmacy restrictions are drawing fire — hospitals reportedly irate after the company followed through on its ultimatum.

The Ollin raise is the one worth tracking. Three hundred and thirty million funds a credible Phase 3 against one of Roche's fastest-growing assets. If that challenger delivers comparable efficacy with a differentiated dosing interval, the retinal disease competitive map redraws in a hurry. Roche has had a remarkably clear runway in retinal — Vabysmo's launch trajectory has been one of the strongest in ophthalmology in years. A well-funded challenger entering pivotal development is exactly the kind of competitive signal Roche's commercial team needs to take seriously now, not after data reads out.

On the regulatory side, two more label expansions landed today beyond Trodelvy. The FDA approved a new breast cancer indication for Pfizer's Ibrance, and Ionis won an expanded label for a triglycerides indication that some are already calling a potential blockbuster.

The Ibrance win should have been a bright spot for Pfizer, but the stock closed down two point seven five percent — still digesting yesterday's sigvotatug vedotin miss. We flagged yesterday to watch for strategic signals around the Seagen portfolio. The market's verdict today is unambiguous: one late-stage ADC failure outweighs an incremental CDK4/6 label expansion. That's a brutal ratio for Pfizer — it means the Street is valuing the Seagen acquisition thesis on the pipeline's ceiling, not its floor, and when the ceiling cracks, the repricing is immediate.

The Ionis story has more running room. Triglyceride-lowering therapies have been a commercial graveyard — fibrates and omega-3s never built the franchises their clinical data promised. Ionis's antisense mechanism is genuinely differentiated, but whether this becomes a blockbuster or a formulary footnote depends entirely on payer willingness to cover a novel-class triglyceride therapy at specialty pricing. That's the gate. And the historical precedent is sobering — the cardiovascular market has repeatedly punished novel mechanisms with payer resistance that clinical differentiation alone couldn't overcome. Ionis needs to show not just efficacy but health-economic value to crack open that gate.

And a broader policy signal — HHS announced a series of reforms designed to fast-track early-phase clinical research in the US, explicitly framed as a response to China's growing role in drug development.

HHS rolls out a repatriation agenda on the same day Lilly deepens a nearly two-billion-dollar China collaboration. Industry is voting with its checkbook while Washington drafts talking points. These reforms could shift IND filing behavior if they meaningfully reduce timelines or early-study costs domestically. But the speed and cost advantages offshore are structural — that gap doesn't close with a single announcement. The juxtaposition today is almost too perfect — it tells you everything about the distance between policy aspiration and commercial reality in cross-border drug development right now.

Looking ahead — the Sangamo bankruptcy auction continues with Lilly and Astellas as lead bidders for the assets. And Nature Medicine formally retracted the PD-1 time-of-day dosing study, citing the amount and nature of the problems identified.

That retraction won't change clinical practice — most oncologists never adjusted infusion scheduling on one retrospective analysis. But for anyone following dosing-time hypotheses in immuno-oncology, it's a sharp reminder that a viral paper and validated science are not the same thing. And more broadly, it underscores how quickly social-media amplification can outrun peer review. The enthusiasm for that study far outpaced its evidentiary foundation, and the retraction is a corrective the field needed.

A former BioNTech employee is suing the company, alleging it cut corners in pancreatic cancer trials. Trial integrity allegations at that profile of company tend to draw regulatory attention regardless of outcome. New FDA leadership also struck a conciliatory note today on rare diseases and staff morale — a tonal shift that matters for anyone navigating orphan drug programs through the agency right now. And separately, Mapp Biopharmaceutical and Gilead antivirals are being deployed in a DRC Ebola trial coordinated by the WHO — a reminder that Gilead's antiviral franchise stays active in global health emergencies alongside this oncology push.

One clock that's ticking — we've previously flagged Novartis's pelacarsen cardiovascular outcome data as expected in the first half of this year. June is running out. If that readout lands next week, it writes a very different chapter on top of what's already been an eventful stretch for Novartis.

And given that Novartis just committed a hundred and five million to Antares on the discovery side, a positive pelacarsen readout would give them a late-stage cardiovascular win and an early-stage oncology platform expansion in the same month. That's a portfolio narrative that rewards the stock beyond any single catalyst.

That's your Pharma Closeout for Wednesday, June 24th. Trodelvy moves to front-line TNBC and sets up the Keytruda fight, Lilly doubles down with Abbisko at one point nine billion, Novartis chases the undruggable, and the ADC class just delivered an approval, a failure, and a restructuring in forty-eight hours. If this briefing keeps you sharp, follow us on Spotify and drop a rating — it helps other pharma professionals find us. We're back tomorrow.

Have a good evening. See you tomorrow. ### Episode Metadata **Title:** FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal; Novartis Bets on Undruggable Targets | Jun 24, 2026 **Description:** Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets, and three ADC stories in two days force a class-level reckoning. **Tags:** Trodelvy, sacituzumab govitecan, Gilead, TNBC, triple-negative breast cancer, FDA approval, Eli Lilly, Abbisko Therapeutics, Novartis, Antares Therapeutics, ADC, antibody-drug conjugate, Pfizer, Ibrance, Ionis, triglycerides, Ollin, Vabysmo, ADC Therapeutics, Zynlonta, HHS, pelacarsen, BioNTech, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #